Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

© The Royal Society of Chemistry 2021. In this chapter, we discuss the rise and rationale for public-private partnerships (PPP) in phenotypic drug discovery (PDD) from both the academic and industrial perspectives. We then give a review of the three most common "precompetitive"PPP in PDD formats, namely collaborative, co-localized and industry-supported, before finally providing an outlook/conclusion, highlighting the factors we feel contribute to successful PDD partnerships, and the directions we feel these partnerships could take to improve outcomes for both partners.

Original publication





Book title

RSC Drug Discovery Series

Publication Date





118 - 139